25 results
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
and the Health, Economic Assistance, Liability Protection, and Schools Act.
“Data Privacy and Security Requirements” means, to the extent relating … with all applicable Data Privacy and Security Requirements, (ii) to the knowledge of the Company, has not been subject to any unauthorized access
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
and the Health, Economic Assistance, Liability Protection, and Schools Act.
“Data Privacy and Security Requirements” means, to the extent relating … with all applicable Data Privacy and Security Requirements, (ii) to the knowledge of the Company, has not been subject to any unauthorized access
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
business and results of operations. ◦ Our ability to comply with data privacy laws and regulations, and uncertainties regarding potential significant … breaches of data privacy. Risks related to our intellectual property, including, among others, that: ◦ If we are unable to obtain and maintain patent
8-K
EX-1.1
PNT
POINT Biopharma Global Inc.
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
unauthorized use, access, misappropriation or modification.
– 19 –
(liii) Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all … prior times were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without
S-3
EX-1.2
PNT
POINT Biopharma Global Inc.
1 Jul 22
Shelf registration
4:13pm
use, access, misappropriation or modification.
(liv) Compliance with Data Privacy Laws. The Company and its Subsidiaries are, and at all prior times … were, in material compliance with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA
424B3
j3xr1dvh
31 Mar 22
Prospectus supplement
11:42am
POS AM
53xql0uok5pstaeyal
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.3
zd6or6b
10 Dec 21
Prospectus supplement
8:24am
424B3
EX-10.1
j62c3qh
10 Dec 21
Prospectus supplement
8:24am
424B3
EX-10.2
cbkffna15
10 Dec 21
Prospectus supplement
8:24am
8-K
EX-10.3
ugeh5jfv03t nn
10 Dec 21
Departure of Directors or Certain Officers
8:17am
8-K
EX-10.2
qy3 4e5whcuto
10 Dec 21
Departure of Directors or Certain Officers
8:17am
8-K
EX-10.1
9a2rdj9klks g42lq
10 Dec 21
Departure of Directors or Certain Officers
8:17am
424B3
v4ud isl5m9028mg
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.6
y4wdadq6piwb 07ny2d8
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.5
bbn2h 64fcgaqfob
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.7
ehn266
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
8-K
EX-10.8
9xalx65h
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am